Cytokinetics Inc
NASDAQ:CYTK
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
31.22
108.06
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cytokinetics Inc
Operating Margin
Cytokinetics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | US |
| Market Cap | 6.1B USD |
| Operating Margin |
-16 298%
|
| Country | FR |
| Market Cap | 6T USD |
| Operating Margin |
-17 527%
|
| Country | US |
| Market Cap | 314.7B USD |
| Operating Margin |
28%
|
| Country | US |
| Market Cap | 147.4B USD |
| Operating Margin |
19%
|
| Country | US |
| Market Cap | 119.4B USD |
| Operating Margin |
40%
|
| Country | US |
| Market Cap | 113.8B USD |
| Operating Margin |
38%
|
| Country | US |
| Market Cap | 94.1B EUR |
| Operating Margin |
-370%
|
| Country | AU |
| Market Cap | 135.4B AUD |
| Operating Margin |
26%
|
| Country | US |
| Market Cap | 82.6B USD |
| Operating Margin |
30%
|
| Country | US |
| Market Cap | 39.3B EUR |
| Operating Margin |
-33%
|
| Country | NL |
| Market Cap | 34.3B EUR |
| Operating Margin |
-22%
|
Cytokinetics Inc
Glance View
Cytokinetics Inc., a clinical-stage biopharmaceutical company, is at the forefront of developing impactful treatments for muscle diseases, leveraging its pioneering expertise in muscle biology and discovery. Founded in 1999 and headquartered in South San Francisco, California, Cytokinetics focuses on harnessing the power of muscle function through its innovative therapies. The company’s lead product candidates, including omecamtiv mecarbil and reldesemtiv, are specifically designed to improve muscle performance in patients suffering from serious conditions like heart failure and amyotrophic lateral sclerosis (ALS). As the demand for effective treatments grows, Cytokinetics is leading the charge to enhance muscle function, aiming not just to prolong life, but to improve patients' quality of life. For investors, Cytokinetics presents a unique opportunity within the growing biopharmaceutical market. The company has strategically partnered with industry leaders, including Amgen, to accelerate the development of its therapeutic portfolio, significantly bolstering its credibility and pipeline potential. With increasing recognition of the importance of muscle health, Cytokinetics stands at an advantageous juncture, positioned to leverage its scientific know-how to unlock substantial value. As clinical trials progress and the company moves closer to potential commercialization, investors have the potential to benefit from Cytokinetics’ innovative approach to addressing unmet medical needs, making it a compelling consideration for those looking to invest in the future of healthcare innovation.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Cytokinetics Inc's most recent financial statements, the company has Operating Margin of -16 297.8%.
You don't have any saved screeners yet
